Clinical Trials Details

Randomized Phase II Trial of Anti-Lag-3 and Anti-PD-1 Blockade vs. Soc in Patients with Recurrent Glioblastoma

IRB Protocol Number

A072201

Clinical Trial Categories

• Brain Cancer

Contact

Clinical Trials at 910-715-2200

How to Participate

Eligibility: 

A randomized trial, testing the effects of the immunotherapy drugs, Relatlimab and Nivolumab, in adult patients with recurrent brain cancer (Glioblastoma).

• 1^st recurrence of glioblastoma following radiation therapy and temozolomide
• No prior use of nivolumab or other anti-PD1 agents
• No active brain metastases or leptomeningeal disease
• No autoimmune disorders that require systemic treatment (except hyperthyroidism or diabetes mellitus)